These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 28116786)

  • 21. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
    Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
    Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
    Hasegawa D; Yoshimoto Y; Kimura S; Kumamoto T; Maeda N; Hara J; Kikuta A; Kada A; Kimura T; Iijima-Yamashita Y; Saito AM; Horibe K; Manabe A; Ogawa C
    Int J Hematol; 2019 Nov; 110(5):627-634. PubMed ID: 31401767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience.
    Colunga-Pedraza JE; González-Llano O; González-Martinez CE; Gómez-Almaguer D; Yáñez-Reyes JM; Jiménez-Antolinez V; Colunga-Pedraza PR
    Pediatr Blood Cancer; 2020 May; 67(5):e28241. PubMed ID: 32159276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India.
    Roy P; Islam R; Saha D; Gogoi M; Kumar Mishra D; Arora N; Parihar M; Krishnan S; Saha V
    Br J Haematol; 2019 Sep; 186(6):861-865. PubMed ID: 31168836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
    Kadia TM; Kantarjian HM; Thomas DA; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Pemmaraju N; Daver N; Wang X; Jain P; Pierce S; Brandt M; Garcia-Manero G; Cortes J; Borthakur G
    Am J Hematol; 2015 Feb; 90(2):120-4. PubMed ID: 25368968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
    Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G; v Stackelberg A; Eckert C
    Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
    Ravandi F; Jorgensen JL; O'Brien SM; Jabbour E; Thomas DA; Borthakur G; Garris R; Huang X; Garcia-Manero G; Burger JA; Ferrajoli A; Wierda W; Kadia T; Jain N; Wang SA; Konoplev S; Kebriaei P; Champlin RE; McCue D; Estrov Z; Cortes JE; Kantarjian HM
    Br J Haematol; 2016 Feb; 172(3):392-400. PubMed ID: 26492205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Burke MJ; Ziegler DS; Bautista F; Attarbaschi A; Gore L; Locatelli F; M O'Brien M; Pauly M; Kormany WN; Tian S; Morris CL; Baruchel A
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29999. PubMed ID: 36215217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
    Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
    Zhou K; Song Y; Zhang Y; Wei X; Fu Y; Yu F; Zhou H; Liu X; Zhou J; Fang B
    Leuk Res; 2017 Nov; 62():29-33. PubMed ID: 28982056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.